Aratana Therapeutics Inc (fka PETX)

[terry hallinan]

Beyond the horizon

From PETX Full Year 2017 Financial Results

https://tinyurl.com/yaduuao2

In February 2018, Aratana announced an animal health research and development collaboration with AskAt Inc. The collaboration includes an option agreement for multiple therapeutic candidates with potential in pain, allergy and cancer, as well as exclusive, worldwide rights to develop and commercialize AT-019, a potent and innovative EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation and other indications.

The rest of the voluminous report looks good to me but this holds particular interest for me and perhaps for Aratana's near future.

Notice the "potent and innovative EP4 receptor antagonist therapeutic candidate" above in the Japanese collaboration and then look at mention in this description of Galliprant that PETX brought through FDA licensing:

It specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation

https://www.galliprantfordogs.com/vet

What does this mean?

- I don't know what it means exactly but blocking that EP4 receptor in dogs relieves the pain and inflammation of osteoarthritis while not preventing the natural lubrication of joints like NSAIDS.

Then going way beyond:

the very recent 3D modeling of the human EP4 receptor

https://tinyurl.com/yb6rpre9

Hey, this is a leap way out of bounds but something I mean to look into because my wife is also terribly crippled by osteoarthritis.

Best, Terry